ArticleFrontiers in microbiology2020
Antimicrobial Peptide Cec4 Eradicates the Bacteria of Clinical Carbapenem-Resistant
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 57 citations in OpenAlex.
- Review
- Article
- Effect of polymyxin resistance evolution on the fitness costs of Acinetobacter baumannii and the underlying mechanisms of polymyxin resistance.Scientific reports · 2026Article
- Effect of the antimicrobial peptide BmKn2-7 in inhibiting Vibrio parahaemolyticus and its role in improving microbiota, immunity and Vibrio resistance in Litopenaeus vannamei.BMC veterinary research · 2026Article
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- In vitro assessment of an antimicrobial peptide against Acinetobacter baumannii persister cells.Scientific reports · 2025Article
- Natural peptides and their synthetic congeners acting againstRSC medicinal chemistry · 2025Review
- Bactericidal Effect of a Novel Phage Endolysin Targeting Multi-Drug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- A chionodracine-derived peptide, KHS-Cnd, as an anti-virulence agent against multidrug-resistantFrontiers in cellular and infection microbiology · 2025Article
- Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.Infection and drug resistance · 2025Review
- Motility of Acinetobacter baumannii: regulatory systems and controlling strategies.Applied microbiology and biotechnology · 2024Review
- A Comprehensive Review of Recent Research into the Effects of Antimicrobial Peptides on Biofilms-January 2020 to September 2023.Antibiotics (Basel, Switzerland) · 2024Review
- Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.Frontiers in pharmacology · 2024Review
- Article
- Recent Advances of Composite Nanomaterials for Antibiofilm Application.Nanomaterials (Basel, Switzerland) · 2023Review
- In vitro and in vivo antibiofilm activity of the synthetic antimicrobial peptide WLBU2 against multiple drug resistant Pseudomonas aeruginosa strains.BMC microbiology · 2023Article
- The Antimicrobial Peptide Octopromycin Suppresses Biofilm Formation and Quorum Sensing inAntibiotics (Basel, Switzerland) · 2023Article
- Emergence and Evolution of OXA-23-Producing ST46Antibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Peptide Cec4 Eradicates Multidrug-ResistantDrug design, development and therapy · 2023Article
- Thoughtful Discussion on Article "Antimicrobial Peptide Cec4 Eradicates Multidrug-Resistant Acinetobacter baumannii in vitro and in vivo" [Letter].Drug design, development and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The drug resistance rate of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.